Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia
Key claim: A Phase II randomized, double-blind, placebo-controlled trial will test TJ0113 capsule at 100, 200, and 400 mg daily for 26 weeks versus placebo in 204 patients with sarcopenia.
Abstract
This study is a randomized, double-blind, multicenter, placebo parallel-controlled Phase II clinical study designed to evaluate the clinical efficacy and safety of TJ0113 Capsule in patients with sarcopenia. The entire study plans to enroll 204 participants with sarcopenia. Eligible participants will be stratified by age (< 70 years or ≥ 70 years to ≤ 80 years or > 80 years) and block-randomized in a 1:1:1:1 ratio into 4 groups (TJ0113 Capsule 100 mg dose group; TJ0113 Capsule 200 mg dose group; TJ0113 Capsule 400 mg dose group; placebo group), with 51 participants per group. Participants in the placebo group will then be re-randomized in a 1:1:1 ratio to the respective dose groups (100 mg, 200 mg, and 400 mg). After randomization, study participants will receive continuous oral administration for 26 weeks with efficacy and safety evaluations, followed by a 1-week follow-up period after the end of treatment.
Why this matters
Sarcopenia has no approved pharmacotherapy, so a Phase II dose-ranging RCT of a novel oral capsule adds another candidate to a small clinical pipeline that already includes IN-207907, AAV-follistatin gene therapy, and repurposed anabolic agents. The finding is a protocol notice rather than an outcome — it marks that TJ0113 has advanced into randomized human testing but tells us nothing yet about whether the intervention alters muscle mass, strength, or physical function.